title: 18F-FDG PET-CT in soft tissue sarcomas: staging, restaging, and prognostic value?
abstract: The aim of this article was to review the current role of PET/computed tomography (CT) in soft tissue sarcomas with respect to staging, restaging, and prognostic value. Fluorine-18-fluorodeoxyglucose PET, for instance, can be very useful in differentiating recurrent disease from scar tissue during follow-up. Other indications of PET-CT are still evolving, especially in the light of new molecular drugs. Different aspects of PET/CT imaging in soft tissue sarcomas are overviewed including organ-specific merits, limitations, and potential pitfalls. Finally, methodological considerations on PET/MRI are also briefly discussed.
authors.affiliation: aDepartment of Nuclear Medicine and Endocrinology, Allgemeines Krankenhaus der Stadt Linz, Medical Faculty of the Johannes Kepler University, Linz bUniversity Clinic of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria cNuclear Medicine & PET/CT Centre Department, Santa Maria della Misericordia Hospital, Rovigo, Italy.
authors.forename: Michael
authors.initials: M
authors.lastname: Gabriel
authors.forename: Domenico
authors.initials: D
authors.lastname: Rubello
mesh_terms: D019788:Fluorodeoxyglucose F18; D006801:Humans; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography / Q000379:methods*; D011379:Prognosis; D012509:Sarcoma / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000473:pathology*; D014057:Tomography, X-Ray Computed / Q000379:methods*
chemical_list: D019788:Fluorodeoxyglucose F18